MCA logo



Immune Checkpoint Inhibitors in Oncology: Nivolumab (Opdivo)

nivolumab (Opdivo) injection oncology cancer

Tumour cells harness multiple resistance mechanisms to evade the host-tumour immune system. Notably, the programmed death 1 (PD1) receptor and its ligands, PD-L1 and PD-L2, play critical roles in T-cell suppression and exhaustion. Overexpression of PD-L1 and PD1 on tumour cells and tumour-infiltrating lymphocytes . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: